Avita Medical Ltd (RCEL) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.327x

Based on the latest financial reports, Avita Medical Ltd (RCEL) has a cash flow conversion efficiency ratio of 0.327x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.44 Million) by net assets ($-16.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Avita Medical Ltd's balance sheet to measure how much of total assets are equity-financed.

Avita Medical Ltd - Cash Flow Conversion Efficiency Trend (1993–2025)

This chart illustrates how Avita Medical Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Avita Medical Ltd cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Avita Medical Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Avita Medical Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Bhiraj Office Leasehold Real Estate Investment Trust
BK:BOFFICE
0.023x
Singular People S.A.
MC:SNG
0.140x
Kelly Partners Group Holdings Ltd
AU:KPG
0.259x
enGene Holdings Inc. Common Stock
NASDAQ:ENGN
-0.120x
Greenland Resources Inc
NEO:MOLY
-0.139x
Mirae Corporation
KO:025560
-0.097x
John Hancock Income Securities Closed Fund
NYSE:JHS
0.031x
Siam Wellness Group Public Company Limited
BK:SPA
0.119x

Annual Cash Flow Conversion Efficiency for Avita Medical Ltd (1993–2025)

The table below shows the annual cash flow conversion efficiency of Avita Medical Ltd from 1993 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Avita Medical Ltd.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 $-16.65 Million $-31.20 Million 1.874x +117.22%
2024-12-31 $4.50 Million $-48.94 Million -10.878x -1303.85%
2023-12-31 $49.06 Million $-38.01 Million -0.775x -243.95%
2022-12-31 $84.74 Million $-19.09 Million -0.225x -30.67%
2021-12-31 $104.62 Million $-18.04 Million -0.172x +45.13%
2020-12-31 $72.40 Million $-22.75 Million -0.314x +66.00%
2019-12-31 $20.83 Million $-19.25 Million -0.924x -83.92%
2017-12-31 $18.99 Million $-9.54 Million -0.502x +60.87%
2016-12-31 $5.12 Million $-6.58 Million -1.284x -48.41%
2015-12-31 $6.85 Million $-5.93 Million -0.865x +25.13%
2014-12-31 $4.22 Million $-4.87 Million -1.155x +1.84%
2013-12-31 $5.53 Million $-6.51 Million -1.177x -83.67%
2012-12-31 $10.46 Million $-6.70 Million -0.641x -27.02%
2011-12-31 $8.55 Million $-4.32 Million -0.505x -174.05%
2010-12-31 $16.99 Million $-3.13 Million -0.184x +46.35%
2009-12-31 $3.98 Million $-1.36 Million -0.343x +36.51%
2008-12-31 $6.93 Million $-3.75 Million -0.541x -97.65%
2007-12-31 $12.96 Million $-3.54 Million -0.273x +60.53%
2006-12-31 $10.98 Million $-7.60 Million -0.693x -6.46%
2005-12-31 $11.15 Million $-7.26 Million -0.651x -69.41%
2004-12-31 $13.09 Million $-5.03 Million -0.384x +21.56%
2003-12-31 $8.66 Million $-4.24 Million -0.490x -304.84%
2002-12-31 $8.25 Million $-997.61K -0.121x -67.46%
2001-12-31 $4.53 Million $-327.44K -0.072x +16.82%
2000-12-31 $5.38 Million $-467.41K -0.087x +42.40%
1999-12-31 $2.72 Million $-409.81K -0.151x -0.12%
1998-12-31 $1.10 Million $-166.28K -0.151x -24.15%
1997-12-31 $1.78 Million $-215.74K -0.121x -16.34%
1996-12-31 $4.98 Million $-519.14K -0.104x -17.25%
1995-12-31 $4.48 Million $-398.66K -0.089x +9.97%
1994-12-31 $5.82 Million $-574.61K -0.099x -2049.66%
1993-12-31 $6.55 Million $33.17K 0.005x --

About Avita Medical Ltd

NASDAQ:RCEL USA Medical Devices
Market Cap
$141.88 Million
Market Cap Rank
#18299 Global
#4231 in USA
Share Price
$4.61
Change (1 day)
-6.68%
52-Week Range
$3.27 - $6.76
All Time High
$55.20
About

AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitili… Read more